Health care giant Johnson & Johnson (NYSE:JNJ) reports second-quarter financial results on Wednesday before the market opens. Here are the earnings estimates, what experts are saying and key items to watch.
Johnson & Johnson Q2 Earnings Estimates
Analysts expect Johnson & Johnson to report second-quarter revenue of $25.05 billion, up from $23.74 billion in last year’s second quarter, according to data from Benzinga Pro.
The company has beaten analyst estimates for revenue in eight straight quarters and in nine of the last 10 quarters overall.
Analysts expect Johnson & Johnson to report second-quarter earnings per share of $2.85, up from $2.77 in last year’s second quarter.
The company has beaten analyst estimates for earnings per share in nine of the last 10 quarters, but beaten estimates in only one straight quarter with a miss in the fourth quarter.
What Experts are Saying
Freedom Capital Markets Chief Market Strategist Jay Woods highlights a strong year-to-date performance by Johnson & Johnson stock in a weekly newsletter.
"Johnson & Johnson looks to continue their winning ways when they report on Wednesday," Woods said.
The market expert said Johnson & Johnson’s stock has had mixed results after earnings, with rallies after four of the last eight reports. The average post-earnings move is +/- 2.1% over the last eight earnings reports.
Looking at the technicals, Woods highlights an uptrend with a consolidation triangle and an upside target of $282, which would set new all-time highs.
"Technically, we like what we see in the overall trend."
Woods sees support at $252 on any dips, with that level serving as a potential new floor.
This is great longer term setup and if there is near term weakness it could give someone on the sideline an opportunity to enter this healthcare giant."
Here are recent analyst ratings and their price targets on Johnson & Johnson stock:
- TD Cowen: Maintained Buy rating, raised price target from $250 to $300
- RBC Capital: Maintained Outperform rating, raised price target from $265 to $287
- Bank of America Securities: Maintained Neutral rating, raised price target from $254 to $263
- Morgan Stanley: Maintained Overweight rating, raised price target from $283 to $284
- Citigroup: Maintained Buy rating, raised price target from $285 to $298
Key Items to Watch
The company has been consistently beating analyst estimates for earnings per share and revenue and investors will be looking for much of the same in the second quarter.
First-quarter results saw strength in Innovative Medicine, Cancer Drugs and MedTech, with Immunology sales declining year-over-year.
Since spinning off the consumer health segment as Kenvue in August 2023, the company is now more reliant on large drugs and its pipeline.
Following the first-quarter results, full-year guidance for earnings per share and revenue was slightly raised.
Investors and analysts may be looking for another beat and raise with shares near their all-time highs.
The earnings report will have several major ETFs on watch, with Johnson & Johnson a member of the Dow Jones Industrial Average. The stock is the 16th largest holding in the SPDR Dow Jones Industrial Average ETF (NYSE:DIA) at 2.92% of assets.
In health care ETFs, Johnson & Johnson is a key player. In the State Street Health Care Select Sector SPDR ETF (NYSE:XLV), JNJ is the second largest holding at 10.64% of assets.
Johnson & Johnson Stock Price Action
Johnson & Johnson stock trades at $253.74 versus a 52-week trading range of $154.80 to $269.43. Johnson & Johnson shares are up 24.3% year-to-date in 2026.
Photo: Shutterstock
Login to comment